Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

NCT02201550 · Completed

Last updated 2026-05-28

This clinical trial is studying how the diabetes medication liraglutide affects certain immune cells in the blood of adults with type 2 diabetes and obesity.

Status Completed The study has finished.

Type Observational

Participants 9 people

Who can join Ages 18–80 · male only

Timeline Started 2013-02 · est. completion 2014-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02201550 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes. The hypotheses are: * Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood * Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood * Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Main thing measured	Change in number of specific immune cells in blood detected by flow cytometry
Sponsor	Hvidovre University Hospital
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02201550 ↗